Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g Vct5 Regulatory News (MIG5)

Share Price Information for Maven I&g Vct5 (MIG5)

Share Price is delayed by 15 minutes
Get Live Data
28.80    0.00 (0.00%)
Bid:
27.80
Ask:
29.80
Spread: 2.00 (7.194%)
Market Cap: £76.28m
MIG5 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g Vct5 Share Chart

Interim Management Statement

9 Oct 2014 12:30

RNS Number : 8996T
Maven Income and Growth VCT 5 PLC
09 October 2014
 



Maven Income and Growth VCT 5 PLC (the Company)

 

Interim Management Statement - quarter ended 31 August 2014

 

This Interim Management Statement, for the quarter ended 31 August 2014, is provided in accordance with Rule 4.3 of the Disclosure and Transparency Rules of the UK Listing Authority and also includes relevant information in respect of the period from 1 September 2014 to the date of issue. This Statement has been prepared solely to provide additional information in order to meet the relevant requirements of the UK Listing Authority's Disclosure and Transparency Rules, and should not be relied on by Shareholders, or any other party, for any other purpose.

 

1.

Financial highlights

 

· Net asset value (NAV)1 of 40.18p per share at 31 August 2014, after payment of the interim dividend, compared to 42.18p per share at 31 May 2014;

· NAV total return2 of 67.63p at 31 August 2014, compared to 68.83p at 31 May 2014; and

· Interim dividend of 0.80p per share in respect of the year ending 30 November 2014, paid on 29 August 2014.

 

1The NAV is unaudited and reflects the closing bid price of quoted securities at 31 August 2014. Unlisted companies are normally valued on a six-monthly basis and the NAV incorporates the Directors' valuation of unlisted investments as at 31 May 2014, adjusted for subsequent events where appropriate.

2NAV total return is the sum of NAV per share and dividends paid per share since launch.

 

2.

Investments and disposals

 

During the quarter ended 31 August 2014, a net amount of £1,559,085 was invested in five unlisted companies and £442,984 was invested in one listed company. In the same period, proceeds of £2,000,000 were realised from the sale of short-dated UK treasury bills; and the realisation of four holdings in unlisted companies generated aggregate proceeds of £697,505 against a cost of £505,291. In addition, the full or partial sale of five AIM quoted investments generated aggregate proceeds of £717,027 against a total cost of £461,986.

 

3.

Recent developments

 

Between 1 September 2014 and the date of this Statement, £529,368 was invested in two unlisted companies and a net amount of £1,991,863 was invested in short-dated UK treasury bills. The full or partial disposals of two AIM quoted investments generated proceeds of £505,468 against a cost of £132,024.

 

 

Other than as described above, and changes in the value of investments quoted on regulated markets, the Board is not aware of any material events during the period from 1 June 2014 to 31 August 2014, or in the period from 1 September 2014 to the date of this announcement, which would have had a material impact on the financial position of the Company.

 

Issued on behalf of the Board

 

Maven Capital Partners UK LLP

Secretary

 

9 October 2014

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSFKLFBZBFLFBV
Date   Source Headline
20th May 202610:20 amRNSAdmission of Further Securities to Trading
15th May 202610:10 amRNSIssue of Equity - Dividend Investment Scheme
12th May 20263:39 pmRNSUnaudited NAV - Dividend Investment Scheme
8th May 20264:10 pmRNSTransaction in Own Shares
28th Apr 20263:55 pmRNSResult of AGM
28th Apr 20261:35 pmRNSResult of AGM
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:30 amRNSAdmission of Further Securities to Trading
14th Apr 202611:11 amRNSIssue of Equity
8th Apr 20269:35 amRNSAdmission of Further Securities to Trading
27th Mar 20265:07 pmRNSOffer for Subscription - Fully Subscribed
25th Mar 202610:59 amRNSAdmission of Further Securities to Trading
25th Mar 20267:00 amRNSAnnual Financial Report
24th Mar 202612:13 pmRNSIssue of Equity
17th Mar 20264:36 pmRNSUnaudited Net Asset Value
3rd Mar 20264:31 pmRNSTransaction in Own Shares - correction
27th Feb 20265:04 pmRNSTransaction in Own Shares
26th Feb 20264:53 pmRNSTransaction in Own Shares
26th Feb 20269:15 amRNSDividend Declaration
18th Feb 20265:01 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:11 amRNSDirector/PDMR Shareholding
17th Feb 202610:58 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:13 amRNSAdmission of Further Securities to Trading
16th Jan 20269:47 amRNSIssue of Equity
14th Jan 20262:44 pmRNSUnaudited NAV - Dividend Investment Scheme
16th Dec 202511:15 amRNSDirector/PDMR Shareholding
16th Dec 202510:30 amRNSIssue of Equity
4th Dec 202510:35 amRNSUnaudited NAV and Second Interim Dividend
13th Nov 20253:45 pmRNSResult of General Meeting
7th Oct 20254:15 pmRNSTransaction in Own Shares
2nd Oct 20254:42 pmRNSPublication of a Prospectus
15th Sep 20251:11 pmRNSNet Asset Value(s)
29th Aug 20257:00 amRNSIssue of Equity
20th Aug 20252:17 pmRNSStatement re Dividend Investment Scheme
17th Jul 20253:21 pmRNSHalf-year Report
16th Jul 20255:33 pmRNSTransaction in Own Shares
16th Jul 20257:08 amRNSStatement re Offer for Subscription
10th Jul 20254:50 pmRNSStatement re Unaudited NAV and Interim Dividend
14th May 20254:46 pmRNSTransaction in Own Shares
9th May 20259:59 amRNSIssue of Equity
6th May 202511:55 amRNSIssue of Equity
2nd May 20251:27 pmRNSUnaudited NAV - Dividend Investment Scheme
29th Apr 20253:20 pmRNSResult of AGM
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
15th Apr 20259:32 amRNSDirector/PDMR Shareholding
4th Apr 20256:22 pmRNSIssue of Equity
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:14 pmRNSDirector/PDMR Shareholding
27th Mar 20251:09 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.